XML 125 R111.htm IDEA: XBRL DOCUMENT v3.20.4
Transition Period Comparative Data (Unaudited) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Transition Period Financial Information [Line Items]                              
Total revenue $ 154.6 $ 145.2 $ 93.2 $ 164.0 $ 195.1 $ 186.3 $ 215.4 $ 216.6 $ 216.8 $ 202.3 $ 299.8 $ 381.4 $ 638.6 $ 851.1 $ 743.7
Costs and expenses:                              
Research and development expense 18.2 17.6 17.4 19.7 18.8 21.3 20.9 21.5 22.4 21.1 35.8 40.1 77.2 85.9 70.8
Change in the fair value of contingent consideration 4.6 (1.1) 0.0 (3.4) (0.1) 0.7 (0.3) 0.0 1.0 0.4 3.5 0.6 (2.8) 1.1 (61.2)
Selling, general, and administrative expense 132.8 124.1 107.4 132.9 134.3 135.5 149.8 140.6 135.2 129.9 256.9 269.8 510.1 555.5 435.0
Goodwill and intangible asset impairment charges     0.0 98.4 1.3 0.0         0.0 1.3 99.7 0.0 0.0
Total costs and expenses 202.8 184.8 161.5 297.7 203.9 207.2 221.0 210.7 210.7 201.1 387.6 411.1 870.3 843.5 621.8
Operating income (loss) (48.2) (39.6) (68.3) (133.7) (8.8) (20.9) (5.6) 5.9 6.1 1.2 (87.8) (29.7) (231.7) 7.6 121.9
Other income (expense):                              
Interest income 0.3 0.4 0.5 0.8 0.8 0.9 0.9 0.7 0.9 0.7 0.7 1.7 3.0 3.2 1.8
Interest expense (2.9) (2.9) (3.1) (2.3) (2.5) (2.9) (3.2) (3.2) (3.4) (2.2) (5.8) (5.4) (10.8) (12.0) (3.2)
Other 0.4 (1.6) 12.4 4.1 (0.9) 0.6 0.2 (0.1) 0.0 1.1 (1.2) (0.3) 16.2 1.2 (0.4)
Total other income (expense) (2.2) (4.1) 9.8 2.6 (2.6) (1.4) (2.1) (2.6) (2.5) (0.4) (6.3) (4.0) 8.4 (7.6) (1.8)
Income (loss) before income tax (50.4) (43.7) (58.5) (131.1) (11.4) (22.3) (7.7) 3.3 3.6 0.8 (94.1) (33.7) (223.3) 0.0 120.1
Income tax benefit (12.5) (28.5) (3.0) (15.9) (3.1) (1.7) (3.4) (3.6) 1.0 1.6 (41.0) (4.8) (23.7) (4.4) (13.0)
Net income (loss) (37.9) (15.2) (55.5) (115.2) (8.3) (20.6) (4.3) 6.9 2.6 (0.8) (53.1) (28.9) (199.6) 4.4 133.1
Net loss attributable to non-controlling interest 0.0 0.0 (0.1) 0.0 0.0 0.0 (0.1) 0.0 0.0 (0.1) 0.0 0.0 (0.1) (0.2) (0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (37.9) $ (15.2) $ (55.4) $ (115.2) $ (8.3) $ (20.6) $ (4.2) $ 6.9 $ 2.6 $ (0.7) $ (53.1) $ (28.9) $ (199.5) $ 4.6 $ 133.3
Earnings (loss) per share:                              
Basic (in dollars per share) $ (0.50) $ (0.20) $ (0.74) $ (1.55) $ (0.11) $ (0.28) $ (0.06) $ 0.09 $ 0.04 $ (0.01) $ (0.71) $ (0.39) $ (2.69) $ 0.06 $ 1.92
Diluted (in dollars per share) $ (0.50) $ (0.20) $ (0.74) $ (1.55) $ (0.11) $ (0.28) $ (0.06) $ 0.09 $ 0.03 $ (0.01) $ (0.71) $ (0.39) $ (2.69) $ 0.06 $ 1.85
Weighted average shares outstanding:                              
Basic (weighted average shares) 75.3 74.7 74.6 74.5 74.4 73.7 73.4 73.3 74.2 73.0 75.0 74.1 74.3 73.5 69.4
Diluted (weighted average shares) 75.3 74.7 74.6 74.5 74.4 73.7 74.8 74.9 76.5 73.0 75.0 74.1 74.3 76.0 72.0
Molecular diagnostic testing                              
Transition Period Financial Information [Line Items]                              
Total revenue $ 143.9 $ 135.7 $ 83.3 $ 150.5 $ 181.1 $ 172.0 $ 196.9 $ 200.5 $ 203.0 $ 189.0 $ 279.6 $ 353.1 $ 586.9 $ 789.4 $ 690.4
Costs and expenses:                              
Costs and expenses 42.7 39.9 32.2 43.1 41.0 41.2 41.6 40.3 44.0 42.3 82.6 82.2 157.5 168.2 148.7
Pharmaceutical and clinical services                              
Transition Period Financial Information [Line Items]                              
Total revenue 10.7 9.5 9.9 13.5 14.0 14.3 18.5 16.1 13.8 13.3 20.2 28.3 51.7 61.7 53.3
Costs and expenses:                              
Costs and expenses $ 4.5 $ 4.3 $ 4.5 $ 7.0 $ 8.6 $ 8.5 $ 9.0 $ 8.3 $ 8.1 $ 7.4 $ 8.8 $ 17.1 $ 28.6 $ 32.8 $ 28.5